R Rubio

Summary

Affiliation: Hospital Universitario
Country: Spain

Publications

  1. doi request reprint Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
    Juan Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    Clin Infect Dis 47:1083-92. 2008
  2. ncbi request reprint Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction]
    Juan Berenguer
    Unidad de Enfermedades Infecciosas, Hospital General Gregorio Maranon, Madrid, Spain
    Enferm Infecc Microbiol Clin 22:160-76. 2004
  3. ncbi request reprint Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy
    Juan Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    J Acquir Immune Defic Syndr 47:422-8. 2008
  4. ncbi request reprint Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy
    Juan Berenguer
    Infectious Diseases Service of Hospital Gregorio Marañón, 28007, Madrid, Spain
    Clin Infect Dis 36:1047-52. 2003
  5. doi request reprint Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients
    J Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    J Antimicrob Chemother 63:1256-63. 2009
  6. doi request reprint Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus
    Juan Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    Hepatology 50:407-13. 2009
  7. doi request reprint Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection
    Juan Berenguer
    HIV Infectious Diseases Unit, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    Clin Infect Dis 46:137-43. 2008
  8. ncbi request reprint Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data
    J Berenguer
    Infectious Diseases Unit, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    J Viral Hepat 14:859-69. 2007
  9. ncbi request reprint Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort
    Juan Berenguer
    Infectious Diseases and HIV Unit, Hospital Gregorio Maranon, Madrid, Spain
    J Acquir Immune Defic Syndr 41:154-9. 2006
  10. ncbi request reprint Food sources of nutrients in the diet of Spanish children: the Four Provinces Study
    M A Royo-Bordonada
    Institute of Health Carlos III, Ministry of Health and Consumer Affairs, Madrid, Spain
    Br J Nutr 89:105-14. 2003

Detail Information

Publications61

  1. doi request reprint Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
    Juan Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    Clin Infect Dis 47:1083-92. 2008
    ..The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been insufficiently analyzed in clinical trials...
  2. ncbi request reprint Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction]
    Juan Berenguer
    Unidad de Enfermedades Infecciosas, Hospital General Gregorio Maranon, Madrid, Spain
    Enferm Infecc Microbiol Clin 22:160-76. 2004
    ..To provide an update of guidelines from the Spanish AIDS Study Group (GESIDA) and the National AIDS Plan (PNS) committee on the prevention of opportunistic infections in adult and adolescent HIV-infected patients...
  3. ncbi request reprint Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy
    Juan Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    J Acquir Immune Defic Syndr 47:422-8. 2008
    ..We analyzed survival, therapeutic response, and prognostic factors in patients with HIV-related Hodgkin lymphoma (HL) treated or not with highly active antiretroviral therapy (HAART)...
  4. ncbi request reprint Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy
    Juan Berenguer
    Infectious Diseases Service of Hospital Gregorio Marañón, 28007, Madrid, Spain
    Clin Infect Dis 36:1047-52. 2003
    ..One-third of patients with PML died despite receipt of HAART; neurologic function improved in approximately one-half of the survivors. A CD4+ cell count of <100 cells/microL was associated with higher mortality...
  5. doi request reprint Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients
    J Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    J Antimicrob Chemother 63:1256-63. 2009
    ..We compared the effectiveness and safety of peg-IFN-alpha2a and peg-IFN-alpha2b, both with ribavirin, against chronic hepatitis C virus (HCV) infection in HIV-infected patients...
  6. doi request reprint Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus
    Juan Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    Hepatology 50:407-13. 2009
    ..CONCLUSION: Our results suggest that the achievement of an SVR after interferon-ribavirin therapy in patients coinfected with HIV/HCV reduces liver-related complications and mortality...
  7. doi request reprint Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection
    Juan Berenguer
    HIV Infectious Diseases Unit, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    Clin Infect Dis 46:137-43. 2008
    ....
  8. ncbi request reprint Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data
    J Berenguer
    Infectious Diseases Unit, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    J Viral Hepat 14:859-69. 2007
    ..3, and the PPV to confirm F > or = 3 was 64.3%. Thus, HGM-2 accurately predicted F > or = 3 among HIV/HCV-coinfected patients. HGM-1 was less accurate at predicting F > or = 2...
  9. ncbi request reprint Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort
    Juan Berenguer
    Infectious Diseases and HIV Unit, Hospital Gregorio Maranon, Madrid, Spain
    J Acquir Immune Defic Syndr 41:154-9. 2006
    ..To analyze the safety and effectiveness of abacavir, lamivudine, and zidovudine (ABC/3TC/ZDV) in antiretroviral therapy (ART)-naive HIV-infected patients...
  10. ncbi request reprint Food sources of nutrients in the diet of Spanish children: the Four Provinces Study
    M A Royo-Bordonada
    Institute of Health Carlos III, Ministry of Health and Consumer Affairs, Madrid, Spain
    Br J Nutr 89:105-14. 2003
    ....
  11. doi request reprint Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program
    M Jesús Pérez-Elías
    Hospital Ramon y Cajal, Madrid, Spain
    Enferm Infecc Microbiol Clin 27:28-32. 2009
    ..The objective of this study was to collect safety data on treatment with fosamprenavir/ritonavir (FPV/r) 700/100mg BID in HIV-infected patients through an expanded access program...
  12. doi request reprint Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study)
    J Arrizabalaga
    Infectious Diseases Unit, H Donostia, San Sebastian, Spain
    HIV Clin Trials 10:48-51. 2009
    ..6% in HIV-infected population. However the prevalence of this allele in HIV-infected patients in Spain has not been established yet...
  13. doi request reprint Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy
    L Valor
    Division of Immunology, University General Hospital Gregorio Marañon, Madrid, Spain
    Vaccine 26:2738-45. 2008
    ..Long-term immunization in patients receiving ART helps to develop HIV-1-specific polyfunctional T cell responses...
  14. ncbi request reprint Hepatitis C in HIV-infected patients--therapeutic approach
    I Fernandez
    Department of Gastroenterology and Hepatology, HIV Unit, Department of Internal Medicine, and Unit of Infectious Diseases, Hospital 12 de Octubre, Madrid, Spain
    Clin Microbiol Infect 8:80-4. 2002
    ..However, the limited amount of available information and the complexities of drug interactions between HAART therapy and immunosuppressive drugs oblige us to be prudent within considering such a procedure...
  15. ncbi request reprint Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations
    V Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Viral Hepat 11:2-17. 2004
    ..These guidelines represent a comprehensive and updated overview on the management of hepatitis B and C in HIV-infected patients...
  16. doi request reprint Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions
    R Rubio
    Internal Medicine Department, HIV Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
    HIV Med 11:545-53. 2010
    ..Atazanavir (ATV) boosted with ritonavir (ATV/r) is a potent, well-tolerated, once-daily protease inhibitor (PI). Few data are available on this agent as a treatment simplification option for patients taking other PIs...
  17. ncbi request reprint Impact of tuberculosis on the course of HIV-infected patients with a high initial CD4 lymphocyte count
    E Manas
    Departamento de neumologia, Hospital Ramon y Cajal, Madrid, Spain
    Int J Tuberc Lung Dis 8:451-7. 2004
    ..To assess the influence of tuberculosis (TB) on the progression of human immunodeficiency virus (HIV) infection in patients without immunological impairment...
  18. doi request reprint Gestational diabetes mellitus in a cohort of HIV-1 infected women
    M I González-Tomé
    Department of Immunodeficiencies, Hospital 12 de Octubre, Madrid, Spain
    HIV Med 9:868-74. 2008
    ..We undertook a prospective study to estimate the prevalence of gestational diabetes mellitus (GDM) and associated risk factors in a cohort of 669 HIV-1 infected women...
  19. ncbi request reprint Study of the validity of a questionnaire to assess the adherence to therapy in patients infected by HIV
    J Martin
    Research Unit, 11th Health Area, Madrid, Spain
    HIV Clin Trials 2:31-7. 2001
    ..The purpose of our study was to examine the validity of a questionnaire to detect nonadherence in HIV-infected patients under antiretroviral treatment...
  20. doi request reprint Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain
    S Monge
    AIDS Research Network, National Centre of Epidemiology, Carlos III Health Institute, Madrid, Spain
    HIV Med 14:273-83. 2013
    ..The objective of the study was to analyse key HIV-related outcomes in migrants originating from Latin America and the Spanish-speaking Caribbean (LAC) or sub-Saharan Africa (SSA) living in Spain compared with native Spaniards (NSP)...
  21. ncbi request reprint Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects
    E Fernandez-Cruz
    Division of Immunology, Hospital General Universitario Gregorio Maranon, Dr Esquerdo 46, 28007 Madrid, Spain
    Vaccine 22:2966-73. 2004
    ..034). The data suggest that therapeutic immunization plus ARTs could influence virologic control...
  22. ncbi request reprint Outcomes of a health education intervention in a sample of patients infected by HIV, most of them injection drug users: possibilities and limitations
    J Martin
    11th Primary Care Area, INSALUD, Madrid, Spain
    AIDS Care 13:467-73. 2001
    ..01) and non-adherent women (p = 0.05). We concluded that HIV-infected patients, mainly IDUs, are not receptive to group educational programmes. The design of future interventions must take into account the patients' characteristics...
  23. ncbi request reprint Paradoxical responses in a cohort of HIV-1-infected patients with mycobacterial disease
    J Olalla
    Unidad de Infección VIH, Servicio de Medicina Interna, Hospital Universitario Doce de Octubre, Madrid, Spain
    Int J Tuberc Lung Dis 6:71-5. 2002
    ..Paradoxical worsening or relapse of opportunistic infections has been described after initiation of highly active anti-retroviral therapy (HAART) in human immunodeficiency virus (HIV) infected patients...
  24. doi request reprint Chagas disease screening among HIV-positive Latin American immigrants: an emerging problem
    J Llenas-García
    HIV Unit, Instituto de Investigación Hospital 12 de Octubre I 12, Universidad Complutense de Madrid, Madrid, Spain
    Eur J Clin Microbiol Infect Dis 31:1991-7. 2012
    ..012). Units dealing with HIV patients from endemic areas of American trypanosomiasis should implement CD screening protocols. Interviews of patients coming from endemic areas should include CD epidemiological questions...
  25. ncbi request reprint [Avascular necrosis of the bone in patients with HIV infection: an emergent problem]
    V J Moreno-Cuerda
    Unidad VIH, Hospital Universitario Doce de Octubre, Madrid, Spain
    Rev Clin Esp 206:392-6. 2006
    ..We cannot rule out antiretroviral treatment as a risk factor for avascular necrosis of the bone. Case-control studies published have not identified antiretroviral treatment as a risk factor probably due to small size of the samples...
  26. ncbi request reprint Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    N Engl J Med 349:1036-46. 2003
    ..We assessed the strategy of substituting nevirapine, efavirenz, or abacavir for a protease inhibitor in patients infected with human immunodeficiency virus type 1 (HIV-1) in whom virologic suppression had been achieved...
  27. doi request reprint Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Acquir Immune Defic Syndr 48:241-4. 2008
    ..Pure X4 and X4R5 dual-tropic viruses may be recognized in approximately 15% of drug-naive HIV-1-positive patients. CCR5 antagonists are active against R5 viruses; therefore, HIV tropism should be known before their prescription...
  28. ncbi request reprint Dietary patterns among children aged 6-7 y in four Spanish cities with widely differing cardiovascular mortality
    F Rodriguez-Artalejo
    Department of Preventive Medicine and Public Health, Universidad Autonoma de Madrid, Madrid, Spain
    Eur J Clin Nutr 56:141-8. 2002
    ..Therefore, this work examines certain anthropometric variables and diet among children aged 6-7 y, living in four Spanish cities with widely differing ischaemic heart disease (IHD) mortality...
  29. ncbi request reprint [Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia]
    Marta Martorell
    Unidad de Hemofilia, Servicio de Farmacia, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Enferm Infecc Microbiol Clin 23:349-52. 2005
    ..86 .g/ml (0.82-4.88 .g/ml) in patients with detectable viral load (p = 0.32). Nevirapine plasma concentrations were 4.41 .g/ml (3.50-6.72 .g/ml) and 3.12 .g/ml (2.44-3.80 .g/ml) respectively (p = 0.18)...
  30. ncbi request reprint Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment
    Andrew Hill
    Liverpool University, Liverpool, UK
    Expert Opin Pharmacother 8:679-88. 2007
    ....
  31. ncbi request reprint Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study
    Hernando Knobel
    Department of Internal Medicine, Infectious Diseases, Hospital del Mar, Barcelona, Spain
    J Acquir Immune Defic Syndr 37:1276-81. 2004
    ..The use of antihistamines remains unclear in this setting. A double-blind placebo-controlled study was performed to evaluate the efficacy of cetirizine in the prevention of nevirapine rash...
  32. ncbi request reprint Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less
    Elena Ferrer
    Infectious Disease Services, Universitari de Bellvitge Hospital, Barcelona, Spain
    AIDS 18:1727-9. 2004
    ..More than 80% of patients who continued with nevirapine had viral loads < 50 copies/ml and CD4 cell counts > 200 cells/pl...
  33. ncbi request reprint Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    Enferm Infecc Microbiol Clin 26:27-31. 2008
    ..The primary endpoint was median change in CD4+ T-cell counts at the end of treatment as compared to baseline. Secondary endpoints were safety and changes in the various T-cell subpopulations...
  34. doi request reprint First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort
    Pere Domingo
    Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, 08025 Barcelona, Spain
    J Antimicrob Chemother 61:1348-58. 2008
    ..A retrospective longitudinal study from the VACH cohort comparing both regimens was performed...
  35. ncbi request reprint Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study
    Lidia Ruiz
    Retrovirology Laboratory, IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Infect Dis 188:977-85. 2003
    ..66; 95% confidence interval, 0.47-0.93; P=.021). A prior STI seems to confer no additional benefit to subsequent virological or immunological outcomes of a salvage regimen...
  36. ncbi request reprint Epidemiological trends of HIV infection in Spain: preventative plans have to be oriented to new target populations (Spanish VACH Cohort)
    Ignacio Suarez-Lozano
    Hospital Infanta Elena, Huelva, Spain
    AIDS 16:2496-9. 2002
  37. doi request reprint Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality
    Miriam J Alvarez-Martinez
    Hospital Clinic IDIBAPS, Universitat de Barcelona, Barcelona, Spain
    Diagn Microbiol Infect Dis 62:34-43. 2008
    ..03 and P < 0.001, respectively). The prevalence of DHPS mutants in Spain is low and is not associated with a worse outcome. Severe respiratory failure at admission is the strongest predictor of PCP outcome...
  38. pmc Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults
    Esteban Ribera
    Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d Hebron, Paseo Vall Hebron 119 129, 08035 Barcelona, Spain
    Antimicrob Agents Chemother 48:4256-62. 2004
    ....
  39. ncbi request reprint Hepatitis C virus and human immunodeficiency virus coinfection in Spain
    Bernardino Roca
    Hospital General, Castellon, Spain
    J Infect 47:117-24. 2003
    ....
  40. ncbi request reprint Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis
    Jesus Oliva
    AIDS 17:637-8. 2003
  41. ncbi request reprint Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis
    Esteban Ribera
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Antimicrob Chemother 59:690-7. 2007
    ..To assess plasma steady-state pharmacokinetics (PK) of rifampicin, isoniazid, saquinavir and ritonavir in HIV and tuberculosis (TB) co-infected patients, and investigate potential interactions between TB drugs and protease inhibitors (PIs)...
  42. ncbi request reprint Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients
    Lluis Castells
    Liver Unit, Department of Medicine, Hospital Universitari Vail d Hebron, Barcelona, Spain
    Antivir Ther 11:1061-70. 2006
    ..To investigate the efficacy of early antiviral treatment for hepatitis C virus (HCV) recurrence in HIV/HCV-coinfected patients undergoing liver transplantation for end-stage liver disease...
  43. ncbi request reprint Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients
    Esteban Ribera
    Infectious Diseases Service, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Antivir Ther 10:605-14. 2005
    ..The purpose of this study was to evaluate the efficacy and safety of a once-daily regimen consisting of didanosine (ddI), lamivudine (3TC) and nevirapine (NVP) for adult antiretroviral-naive patients with HIV-1 infection...
  44. ncbi request reprint Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study)
    Esteban Ribera
    Infectious Diseases Service, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Acquir Immune Defic Syndr 40:317-23. 2005
    ....
  45. ncbi request reprint Value of culture and nested polymerase chain reaction of blood in the prediction of relapses in patients co-infected with leishmania and human immunodeficiency virus
    Cristina Riera
    Laboratori de Parasitologia, Facultat de Farmacia, Universitat de Barcelona, Barcelona, Spain
    Am J Trop Med Hyg 73:1012-5. 2005
    ..However, the presence of viable parasites during post-treatment follow-up increased the probability of relapse and showed that culture positivity could be a good relapse marker...
  46. ncbi request reprint Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine
    Cesar Fisac
    Nutrition Section, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
    AIDS 19:917-25. 2005
    ..To evaluate the 24-month metabolic and morphological benefits obtained from replacing the protease inhibitor (PI) in a regimen with nevirapine, efavirenz or abacavir...
  47. ncbi request reprint Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen
    Esteban Ribera
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Paseo Vall Hebron 119 129, 08035 Barcelona, Spain
    AIDS 20:1131-9. 2006
    ..To assess the pharmacokinetics and tolerability of lopinavir (LPV), ritonavir (RTV) and atazanavir (ATV) as a double-boosted protease inhibitor regimen in HIV-infected adults...
  48. ncbi request reprint Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial
    Jose M Miro
    Institut d Investigacions Biomediques August Pi Sunyer Hospital Clinic, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 43:79-89. 2006
    ..To our knowledge, no randomized trials have evaluated whether prophylaxis against toxoplasmic encephalitis can be safely discontinued after the CD4+ T cell count increases in response to highly active antiretroviral therapy...
  49. ncbi request reprint [Changing trends in HIV epidemics: recent diagnoses in the Spanish VACH cohort (2000-2002)]
    Ramon Teira
    Servicio de Enfermedades Infecciosas, Hospital de Basurto, Bilbao, Spain
    Enferm Infecc Microbiol Clin 23:213-7. 2005
    ..Studying the changing trends of HIV epidemics is a useful means of evaluating the results of current preventive plans as well as of defining future needs and objectives...
  50. ncbi request reprint Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen
    Cecilia Cabrera
    IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    AIDS 20:2075-80. 2006
    ..To analyse the genetic changes in the gp41 protein in HIV-infected patients with detectable plasma viraemia receiving a long-term salvage enfuvirtide regimen...
  51. ncbi request reprint Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients
    Manuel Crespo
    Infectious Diseases Department, Spain
    AIDS 21:477-81. 2007
    ..To investigate the utility of a week-4 virological response for sustained response prediction in hepatitis C virus (HCV) genotype 3/HIV-co-infected patients treated with interferon and ribavirin for 24 weeks...
  52. ncbi request reprint Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vail d Hebron, Universitat Autonoma de Barcelona, Spain
    Antivir Ther 12:1217-23. 2007
    ..Therefore, it has been suggested that monitoring RBV serum levels could be used to drive dose modification and to optimize management of HCV-infected patients receiving combination treatment...
  53. ncbi request reprint Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients
    Esteban Martinez
    Hospital Clinic, Barcelona, Spain
    AIDS 21:367-9. 2007
    ..In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation...
  54. ncbi request reprint Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    J Acquir Immune Defic Syndr 44:139-47. 2007
    ..To assess lipoatrophy, other toxicities, and efficacy associated with abacavir as compared with stavudine in HIV-infected antiretroviral-naive patients...
  55. ncbi request reprint Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study
    Fernando Laguna
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Instituto de Salud Carlos III, C Sinesio Delgado 12, 28029 Madrid, Spain
    J Antimicrob Chemother 52:464-8. 2003
    ..0006). The efficacy of ABLC is similar to meglumine antimoniate, but the severity of toxicity in the treatment of HIV-VL is lower with ABLC...
  56. ncbi request reprint Lactic acidosis related to nucleoside therapy in HIV-infected patients
    Vicenc Falco
    Infectious Diseases Division, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, P masculine Vall d Hebron 119 129 08035, Barcelona, Spain
    Expert Opin Pharmacother 4:1321-9. 2003
    ..Therapy is based on supportive measures and discontinuation of all antiretroviral drugs. Administration of essential vitamin coenzymes, electron acceptors and L-carnitine may be useful in some cases...
  57. ncbi request reprint Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors
    Esteban Martinez
    Hospital Clinic IDIBAPS, Barcelona, Spain
    Antivir Ther 8:403-10. 2003
    ..Whether a therapeutic approach addressed to those metabolic abnormalities may have any impact on body fat is not clear...
  58. ncbi request reprint Liver transplantation in HIV-HCV coinfected patients: a case-control study
    Lluis Castells
    Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d Hebron, Universidad Autonoma de Barcelona, Barcelona, Spain
    Transplantation 83:354-8. 2007
    ..1%) of the control group and one patient (20%) of the HIV group presented a sustained virologic response (P=NS). Short- to midterm results of LT in HIV-HCV co-infected patients were excellent and similar to non-HIV patients...
  59. ncbi request reprint [Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection]
    Nuria Vallejo Camazón
    Servicios de Cardiología, Hospital General Vall d Hebron, Barcelona, Spain
    Rev Esp Cardiol 55:878-81. 2002
    ..We report a case of QT prolongation and development of ventricular arrhythmia in one HIV patient that started with intravenous clarithromycin and cotrimoxazole therapy...
  60. ncbi request reprint Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature
    Vicente Falco
    Infectious Diseases Division, Hospital Vall d Hebron, 08035 Barcelona, Spain
    Clin Infect Dis 34:838-46. 2002
    ..17; 95% CI, 0.04-0.73). We conclude that specific therapy with cofactors may improve the outcome for patients with this syndrome...
  61. ncbi request reprint [Spanish recommendations for proper use of enfuvirtide]
    Esteban Ribera
    Hospital Vall d Hebron, Barcelona, Espana
    Enferm Infecc Microbiol Clin 25:131-42. 2007
    ....